Aqilion to present results at scientific events

AQILION AB (publ) will present updates on the Company's progress and scientific results at two different scientific conferences in May. The presentations will cover the pipeline programs AQ280 for the treatment of eosinophilic esophagitis and AQ312 for the treatment of ulcerative colitis.

Johan Lund, CSO, will present Aqilion's pipeline with a special focus on the pipeline programs AQ280 and AQ312 at the 20^th Annual Conference of International Drug Discovery and Science technology (IDDST) in Osaka, Japan, May 22-24, (https://www.iddst.com/iddst2024/default.asp ).

Anneli Tinnerholm, Senior Director of Clinical Operations, Wayne Russell, Senior Director of Translational Biology and Innovation, and Jan Törnell, CMO, will present scientific posters with the results from the Phase 1 study of AQ280 and new preclinical data describing the drug candidate AQ312 at Digestive Disease Week (DDW) 2024 in Washington from May 18-21, (https://ddw.org).

AQ280

Aqilion is developing the drug candidate AQ280 as a potential treatment for Eosinophilic Esophagitis (EoE). AQ280 is an oral, small-molecule selective JAK1 inhibitor. JAK1 is a kinase, that accelerates inflammatory processes, which control conditions. Inhibiting its mechanism may facilitate symptom mitigation and

disease progression in chronic inflammatory diseases.

AQ312

Drug candidate AQ312 targets a core receptor known as AhR for the treatment of inflammatory bowel diseases (IBD). Modulating the AhR receptor stimulates the body’s innate immune system to boost the quantity of cells in the intestinal lining that have the ability to mitigate inflammation. A drug that reduces inflammation specifically in the colon could potentially alleviate symptoms for patients with ulcerative colitis (UC).

For more information, please contact:
Sarah Fredriksson, CEO, AQILION AB, + 46 (0)70 261 4575, sarah.fredriksson@aqilion.com

About Aqilion

Aqilion is a biotech company that focuses on developing innovative new treatments for diseases caused by chronic inflammation and dysfunctional immune reactions such as autoimmune diseases.

We identify innovative ideas that could potentially lead to new medications and refine them into commercially interesting projects. The innovation approach is based on solid scientific grounds, in disease areas where we, with reasonable assumptions, can understand the underlying biology, clinical relevance of the mechanism, potential patient benefit and the likelihood for finding a partner.

The company is mainly active in the early phases of drug discovery, from idea to proof-of-concept in clinical trials. Aqilion executes it’s development programs in a partly virtual organization in close collaboration with selected partners, with specific expertise in drug development.

AQILION AB (publ) is a Swedish public limited company headquartered in Helsingborg, Sweden. www.aqilion.com